EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease
BioArctic AB's partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization…
BioArctic AB's partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization…
A huge step forward in dementia research has been hailed a truly historic moment by…
Eisai Co., Ltd. and Biogen Inc. have announced positive topline results from Eisai’s large global…
The FDA shocked many life sciences observers by greenlighting Biogen’s treatment candidate for Alzheimer’s last…
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
Hopes of seeing an approved treatment for the inflammatory bowel condition pouchitis have been dashed…
The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including…
BC Platforms and Microsoft will be working with Biogen and the Accelerated Cure Project to…
May 5, 2017, saw the first FDA approval for an amyotrophic lateral sclerosis (ALS) drug…
Probiodrug has disclosed encouraging results of its latest Phase IIa trial to assess its lead…
With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis.…
Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s…